News | January 02, 2008

Abiomed Honors Tufts-New England Medical Center for Heart Recovery

January 3, 2008 – Abiomed Inc. selected Tufts-New England Medical Center (Tufts-NEMC) as a “Center of Excellence” for its cardiac program, having achieved outstanding clinical outcomes with the recovery of the native heart.

As a Center of Excellence, Tufts-NEMC will share best practices related to VAD implantation and patient care with other hospitals and medical centers. This award is granted to top institutions in the country for achieving significant clinical outcomes and their focus on recovery of the native heart. Tufts-NEMC’s outcomes are among the best in the country.

“Center of Excellence designation further exemplifies our commitment to native heart recovery and the total wellbeing of our patients,” said Afshin Ehsan, M.D., Division of Cardiothoracic Surgery at Tufts-NEMC. “Tufts-New England Medical Center’s continued success in recovering patients’ hearts, evidenced by the recovered patients able to join us today, is due to the clinical excellence and dedication of our entire cardiac team.”

Tufts-NEMC has supported more than 20 patients with Abiomed technologies. In addition, as the only Abiomed training center in New England, Tufts-NEMC conducts ongoing certification training for other hospitals.

Abiomed is a provider of medical technologies that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery, enabling the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart.

For more information: and

Related Content

Sponsored Content | Videos | Cardiovascular Ultrasound| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Italian Boy Becomes Youngest Patient Bridged to Transplant With SynCardia Total Artificial Heart

Andrei, 12, is the world’s youngest patient to be bridged to transplant with the SynCardia Total Artificial Heart. He is pictured after his heart transplant with his surgeon, Antonio Amodeo, M.D., at Bambino Gesù Children’s Hospital in Rome, Italy. Photo courtesy of Business Wire.

News | Congenital Heart| June 22, 2017
A 12-year-old boy at Bambino Gesù Children’s Hospital in Rome, Italy, has become the world’s youngest patient to be...
Abiomed Impella CP pVAD, third-generation CP
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — Abiomed Inc.
tandemLife Tandemheart priming tray cleared by FDA
Technology | Hemodynamic Support Devices| June 12, 2017
June 12, 2017 — TandemLife began its commercial launch of the TandemLife Priming Tray, a new product designed to simp
Sponsored Content | Videos | Cardiovascular Ultrasound| May 26, 2017
This video, provided in partnership with the American Society of Echocardiography (ASE), is titled "Intraoperative Tr
Impella CP study to investigate door to left ventricular unloading time
News | May 09, 2017
May 9, 2017 — The first patient has been enrolled in the U.S.
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD)| May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices| April 28, 2017 | Dave Fornell
Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment prot
Sponsored Content | Videos | Ventricular Assist Devices (VAD)| April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Overlay Init